Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 45,251

Document Document Title
WO/2018/070521A1
In one embodiment, the present invention addresses the problem of: providing an agent for inhibiting a lectin pathway and an alternative pathway; and others. In one embodiment, the present invention relates to: a fusion polypeptide conta...  
WO/2018/070370A1
This oxybutynin-containing transdermal absorption preparation is provided with: a support layer which comprises a base fabric and at least a part of which has water-repellent properties; and an adhesive layer which is layered on one surf...  
WO/2018/069210A1
The compounds of a certain formula 1, in which R1, R2 and R3 have the meanings as given in the description, are novel effective inhibitors of phosphodiesterase type 4.  
WO/2018/071784A1
Methods of treatment comprising administering a compound having structure (I), N O O2 S NH N N O O, (I) or a pharmaceutically acceptable salt thereof, or administering a pharmaceutical composition comprising the compound of structure (I)...  
WO/2018/068759A1
The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring brid...  
WO/2018/069222A1
The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compoun...  
WO/2018/070524A1
Provided are: a screening method suited for screening for a blood IgA production inhibitor, a blood IgA production accelerating agent, or a prophylactic or therapeutic agent against diseases caused by excessive IgA in the blood; a blood ...  
WO/2018/067705A1
Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include thiolated nitro fatty acids. The methods of various embodiments include admi...  
WO/2018/067857A1
The present invention is directed to methods of treating a human patient with acute kidney injury.  
WO/2018/067709A1
Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include reversible nitroxide derivatives of nitroalkenes. The methods of various emb...  
WO/2018/067740A1
In some aspects, the disclosure relates to activin and/or GDF antagonists and methods of using activin and/or GDF antagonists to treat, prevent, or reduce the progression rate and/or severity of kidney disease, particularly treating, pre...  
WO/2018/066646A1
The present invention addresses the problem of finding a novel medicine which has an excellent tryptophanase inhibitory effect, suppresses indoxyl sulfate production in blood to thereby prevent deterioration of renal function, and thus c...  
WO/2018/059534A1
Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor.  
WO/2018/064112A1
The present invention provides compositions and methods comprising novel arginase inhibitors to treat and prevent Acute Kidney Injury.  
WO/2018/062122A1
[Problem] To provide a novel composition that is capable of promoting the secretion of an atrial natriuretic peptide. [Solution] A composition for promoting the secretion of an atrial natriuretic peptide, said composition comprising a co...  
WO/2018/060704A1
Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduct...  
WO/2018/062233A1
The present invention provides a compound represented by formula (I), which is usable as a cationic lipid facilitating the introduction of a nucleic acid into a cell, or the like, and a composition, or the like, containing the compound.  
WO/2018/053588A1
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.  
WO/2018/055526A1
The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.  
WO/2018/055527A1
The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.  
WO/2018/055524A1
The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.  
WO/2018/054357A1
Provided are a pharmaceutical composition comprising mineralocorticoid receptor antagonist and a use thereof. By orally administrating a pharmaceutical composition to a patient suffering from chronic kidney disease in need of treatment t...  
WO/2018/054354A1
Provided is an application of an SRC homology region 2-containing protein tyrosine phosphatase-1 agonist as represented by formula (I) in preparation of drugs for treating and reducing fibrosis. Preferably, the agonist is SC-43; the fibr...  
WO/2018/052082A1
This Lin28a activator includes, as an active ingredient, a polysaccharide which contains at least one substance selected from the group consisting of ribose, xylose, and derivatives of each. A monocyte dedifferentiation inducer includes,...  
WO/2018/053004A2
Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions com...  
WO/2018/051298A1
The present disclosure relates to polymers comprising conjugates of cyclodextrin or derivatives thereof and a linker moiety, and their application in treating lipid storage disorders by the removal of lipids such as cholesterol from cell...  
WO/2018/050510A1
The invention relates to novel 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides, to methods for producing the same, to the use thereof either alone or in combination in the treatment and/or prevention of diseases and to their ...  
WO/2018/047036A1
The embodiments include methods of ameliorating or preventing the worsening or progression and/or ameliorating or preventing the worsening or lack of improvement of symptoms of BPH in mammals, using compositions containing compounds base...  
WO/2018/041563A1
The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes...  
WO/2018/035617A1
Provided are compounds having the Formula I : AT(RM)V-(LR)W-R3CysX1X2X3X4X5X6ProX7ThrCysR2XR3(R4)S(R5)1, (1); pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided is the use of these compounds...  
WO/2018/039581A1
The present disclosure is directed to the use of HDAC6 inhibitors for the treatment of renal diseases and disorders, including ciliopathy, Von Hippel-Lindau (VHL) disease, renal cystogenesis, renal cell carcinoma, and Tuberous Sclerosis ...  
WO/2018/035751A1
A Cordyceps sinensis health supplement containing traditional Chinese medicine extracts and a preparation method therefor. The health supplement comprises the following raw materials in parts by weight: 20-40 parts of Folium Mori extract...  
WO/2018/037580A1
[Problem] To provide a therapeutic agent for treating and/or improving nephropathy caused by glucose. [Solution] This therapeutic agent for nephropathy caused by glucose is characterized by having a sodium / glucose cotransporter 2 (SGLT...  
WO/2018/039386A1
The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1,...  
WO/2018/039051A1
The present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use as a human PDE1 inhibitor.  
WO/2018/034883A1
The invention provides compounds of the formula: (A), pharmaceutically acceptable salts, pharmaceutical compositions thereof, and methods of using these compounds, salts, or compositions to treat hyperphosphatemia, chronic kidney disease...  
WO/2018/032513A1
An application of an astragaloside for preparing a pharmaceutical product for preventing and treating type 2 diabetic nephropathy. The astragaloside can reduce urine albumin excretion of a db/db mouse with type 2 diabetes, mitigate a pat...  
WO/2018/031845A1
Embodiments of the invention provide pharmaceutical compositions and methods for preventing and treating disease and promoting the health in subjects at risk of cardiovascular disease and/or kidney disease. Additional embodiments of the ...  
WO/2018/030382A1
According to the present invention, a compound represented by general formula (I), a tautomer, stereoisomer or pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer or the pharmace...  
WO/2018/025596A1
In an operating room 8, about 40 mL of the bone marrow fluid 10 of a patient is sampled and housed in a collection tube 11. Then, the collection tube 11 is conveyed into an isolator 2 in a sterile state. In the isolator 2, the bone marro...  
WO/2018/024110A1
An MG53 mutant. A coiled-coil-SPRY region of the wild-type MG53 is provided with amino acids among which at least one amino acid is deleted and/or mutated to any other amino acid except serine or threonine. The prevent invention comprise...  
WO/2018/024716A1
The present invention refers to a process for preparing a salt solution comprising sodium chloride and extracts of parts of officinal plants, preferably extracts of olive tree leaves; the invention is further directed to the salt solutio...  
WO/2018/025129A1
The present invention relates to a pharmaceutical composition for use in the treatment of prostate pathologies. The present invention further relates to a composition comprising a mixture which comprises or, alternatively, consists of an...  
WO/2018/024504A1
The present disclosure relates to L-glutamine for use in preserving, improving or restoring kidney function or for decelerating and/or attenuating a decline in kidney function.  
WO/2018/025982A1
Provided is a treatment method etc. for example against novel IL-8 related diseases, using an IL-8 signal inhibitor. Alternatively, provided is a treatment method etc. for example against known or novel IL-8 related diseases, using a nov...  
WO/2018/019244A1
The present invention relates to salts of 2,6-dimethylpyrimidone derivative and uses of the salts. The present invention also relates to a pharmaceutical composition comprising the salts or a combination thereof, and uses of the salts or...  
WO/2018/019106A1
Provided are a nitrogenous heterocyclic aromatic compound, a preparation method therefor, a pharmaceutical composition thereof, and an application thereof. The nitrogenous heterocyclic aromatic compound can be used for treating and/or pr...  
WO/2018/022815A2
Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.  
WO/2018/022815A3
Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.  
WO/2018/020355A1
The embodiments include methods of preventing or reducing the incidence of acute urinary retention in mammals susceptible to developing acute urinary retention, and to methods of reducing the incidence of clinically detected prostate can...  

Matches 1 - 50 out of 45,251